Repeated implantation failure
Conditions
Interventions
Control group:Placebo
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Participants who meet the RIF infertility diagnostic criteria for frozen-thawed embryo transfer (FET) after in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), or Participants who meet the diagnostic criteria for RIF infertility by preimplantation genetic testing for aneuploidy (PGT-A); 2. Married women aged 18-40 years (excluding the critical value); 3. Married women who have experienced two or more failed embryo transfer cycles; 4. Be able to understand the informed consent, voluntarily participate in this clinical trial and sign the informed consent; 5. Be able to complete the trial in compliance with the research protocol.
Exclusion criteria
Exclusion criteria: 1. Women who currently receiving any corticosteroid or immunosuppressive therapy, such as prednisone, cyclosporine, and azathioprine, participants receiving these drugs require a 2-month washout period before screening; 2. Women with known autoimmune diseases such as systemic lupus erythematosus (SLE), antiphospholipid syndrome, Sjogren's syndrome and scleroderma; 3. Women diagnosed with diseases affecting the uterine cavity, such as uterine malformations and submucosal fibroids; 4. Participants with abnormal karyotype (excluding chromosomal polymorphisms) or their partners; 5. Women with recurrent pregnancy loss, defined as two or more clinical pregnancy failures confirmed by ultrasonography or histopathology; 6. Women with assisted reproductive technology and/or medical contraindications to pregnancy; 7. Participants with thin endometrium (< 6 mm) and insensitive or ineffective hormonal drug therapy for endometrial preparation; 8. Known to be allergic to quinolines or have a history of related allergies. 9. Except for the routine medications used during the transplantation, the participant is currently receiving or has been treated with aspirin, Fragmin, Clexane and Heparin during the trial period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| live birth rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| biochemical pregnancy rate;clinical pregnancy rate;embryo implantation rate;early abortion rate;ongoing pregnancy rate;Birth weight;pregnancy and perinatal complications;Congenital Anomaly;Other adverse events; | — |
Countries
China
Contacts
Public ContactLi Rong
Peking University Third Hospital
Outcome results
None listed